# NATIONAL ASSEMBLY

**FOR WRITTEN REPLY**

**QUESTION NO. 1056**

**DATE OF PUBLICATION IN INTERNAL QUESTION PAPER: 07 MAY 2021**

**(INTERNAL QUESTION PAPER NO. 12)**

**Ms H Ismail (DA) to ask the Minister of Health:**

What are the relevant details of the specific impact of COVID-19 vaccines approved for vaccination in the Republic, on persons, including with regard to (a) the different age groups and (b) persons with comorbidities, with reference to how effective and/or for how long the vaccines will provide protection against re-infection?

###### NW1242E

**REPLY:**

Only a marginal reduction in efficacy has been noted the elderly (>60-65 years) in the trials conducted to date. With regards to comorbidities, current trials have shown no difference in efficacy compared to persons without comorbidities. Theoretically they may be less effective in persons with decreased immune system, however the limited trials to date have not shown this.

There is currently no data on how long the vaccines will provide protection against re-infection.

END.